首页> 美国卫生研究院文献>Springer Open Choice >Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

【2h】

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

机译：TOURMALINE-MM3研究中不良事件管理在多发性骨髓瘤移植后艾达唑单抗维持中的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

CONSORT diagram. Reproduced with permission from Dimopoulos MA, Gay F, Schjesvold F et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. 2019;393:253–264

机译：CONSORT图。经Dimopoulos MA，Gay F，Schjesvold F等人许可复制。自体干细胞移植（TOURMALINE-MM3）后的口服依他佐米维持治疗：一项双盲，随机，安慰剂对照的3期试验。 2019; 393：253–264

著录项

期刊名称 Springer Open Choice
作者
Martin Kaiser; Meral Beksaç; Nina Gulbrandsen; Fredrik Schjesvold; Roman Hájek; Philippe Moreau; Felipe de Arriba de la Fuente; María-Victoria Mateos; Sharon West; Andrew Spencer; S. Vincent Rajkumar; Kaveri Suryanarayan; Michael Czorniak; Cong Li; Zhaoyang Teng; Richard Labotka; Meletios A. Dimopoulos;
展开▼
作者单位

展开▼
年(卷),期 -1(99),8
年度 -1
页码 -1
总页数 12
原文格式 PDF
正文语种
中图分类外科学;
关键词
Adverse events; Ixazomib; Maintenance therapy; Multiple myeloma; Safety;

机译：不良事件;依沙米布;维持疗法;多发性骨髓瘤;安全性;

相似文献

外文文献
中文文献
专利

1. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma [J] . Annals of hematology . 2020,第8期

机译：在多发性骨髓瘤中移植后Ixazomib维持的TaIlmaline-MM3研究中的不良事件管理
2. Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial [J] . Dimopoulos Meletios A., Gay Francesca, Schjesvold Fredrik H., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：具有口服蛋白酶体抑制剂（PI）的维持治疗Ixazomib在新诊断的多发性骨髓瘤（NDMM）患者中的自体干细胞移植（ASCT）之后显着延长了无进展的存活率（PFS）：第3期Tourmaline-MM3试验
3. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma [J] . Kumar Shaji, Moreau Philippe, Hari Parameswaran, British Journal of Haematology . 2017,第4期

机译：与IXAZOMIB PLUS Lenalalomide / DexameLisoons相关的不良事件的管理，复发/难以多发性骨髓瘤
4. Blocking IL-1 Beta to Prevent Progression to Multiple Myeloma [C] . Lust J. Donovan K. Joint Conferences of the International Cytokine Society and the International Society for Interferon and Cytokine Research . 2011

机译：阻断IL-1β以防止进展到多个骨髓瘤
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma [O] . Shaji Kumar, Philippe Moreau, Parameswaran Hari, -1

机译：埃沙佐米联合来那度胺/地塞米松治疗复发/难治性多发性骨髓瘤相关不良事件的处理
7. Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma [O] . Martin Kaiser, Meral Beksaç, Nina Gulbrandsen, 2020

机译：矫正：逆转骨瘤后移植后Ixazomib维持的逆向事件管理

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

摘要

著录项

相似文献

相关主题

期刊订阅